OncoMatch/Clinical Trials/NCT06340204
Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma
Is NCT06340204 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Irinotecan Hydrochloride Liposome for ewing sarcoma.
Treatment: Irinotecan Hydrochloride Liposome — The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: cytotoxic chemotherapy (doxorubicin, vincristine, cyclophosphamide, ifosfamide, etoposide) — standard Ewing Sarcoma chemotherapy
Prior treatment consisted of standard Ewing Sarcoma chemotherapy agents including doxorubicin, vincristine, cyclophosphamide, ifosfamide and etoposide
Lab requirements
Blood counts
Adequate organ function. Known persistent (> 4 weeks) ≥ Grade 2 neutropenia, ≥ Grade 2 thrombocytopenia or > Grade 3 anemia from prior cancer therapy [excluded].
Kidney function
Adequate organ function.
Liver function
Adequate organ function.
Adequate organ function. Known persistent (> 4 weeks) ≥ Grade 2 neutropenia, ≥ Grade 2 thrombocytopenia or > Grade 3 anemia from prior cancer therapy [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06340204 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received cytotoxic chemotherapy.
Is there an age limit?
Yes. Patients must be 40 years or younger and at least 8 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages